In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
Get the detailed quarterly/annual income statement for Recursion Pharmaceuticals, Inc. (RXRX). Find out the revenue, expenses and profit or loss over the last fiscal year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results